Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection
European Journal of Neurology, Article first published online: 31 OCT 2015, DOI: 10.1111/ene.12844
E. M. Mowry1,*, D. Pelletier2, Z. Gao3, M. D. Howell3, S. S. Zamvil4 andE. Waubant4
Every 10 ng/ml more vitamin D associated with
- 8 ml more gray matter volume
- 35% reduction in risk of MS relapse (P = 0.096)
See also VitaminDWiki
- Fewer white spots in MRI brain scans if had more vitamin D – Jan 2014
- Multiple Sclerosis Treatment and Research -Vitamin D presentations at European Congress Oct 2015
- Multiple Sclerosis web survey: 82 percent take vitamin D (2000-5000 IU), strong association with latitude - Aug 2015
- Multiple Sclerosis prevention by Vitamin D: 10 year, 30 million dollar trial - Sept 2013
- Appears that Vitamin D can induce remission in recent Multiple Sclerosis
- Prevention with vitamin D in Multiple Sclerosis is logical – editorial April 2013
The articles in both MS and Meta-Analysis are:
- Multiple Sclerosis treatment not helped by small doses of vitamin D (yet again) – meta-analysis Jan 2024
- Multiple Sclerosis 2X-3X more likely if poor Vitamin D Receptor – Meta-analysis Feb 2020
- Multiple Sclerosis: 10 percent fewer relapses for each 10 ng higher level of vitamin D – Meta-analysis April 2020
- Multiple Sclerosis 40 percent more likely if mother had low vitamin D – meta-analysis Jan 2020
- Risk of Multiple Sclerosis varies with the Vitamin D Receptor – meta-analysis Dec 2019
- MS not treated by Vitamin D (a few old studies using small doses) – Meta-analysis July 2018
- Multiple Sclerosis treated when use high doses of vitamin D – meta-analysis May 2018
- Fewer Multiple Sclerosis lesions when supplemented with Vitamin D – meta-analysis May 2017
- Multiple Sclerosis and small doses of Vitamin D – meta-review March 2016
- Multiple sclerosis patients have 15 ng lower levels of vitamin D – meta-analysis June 2014
- Multiple Sclerosis and the Vitamin D Receptor – meta-analysis July 2014
- Multiple Sclerosis: number needed to treat with vitamin D may be as low as 1.3 – Meta-analysis Oct 2013
- No association between Multiple Sclerosis relapses and being treated with vitamin D–meta-analysis May 2013
- Multiple Sclerosis 23 percent more likely if born in April vs. Oct – meta-analysis Nov 2012
MS Intervention using Vitamin D:
- 54,000 IU of vitamin D daily with no Calcium (1,000 IU per kg: Coimbra protocol) – July 2024
- Multiple Sclerosis treated equally by UVB and weekly 50,000 IU of Vitamin D – RCT July 2023
- Multiple Sclerosis is again not fought by 5,000 IU vitamin D daily (need at least 10X more) – RCT May 2023
- 53 Multiple Sclerosis patients somewhat helped by 10,000 IU of vitamin D (vs, 30,000 virtually cured by 10X as much) – Jan 2020
- Multiple Sclerosis treated by 50,000 IU Vitamin D bi-weekly plus Omega-3 – RCT July 2018
- Multiple Sclerosis Relapsing-Remitting rate reduced 30 percent by addition of 14,000 IU vitamin D daily – RCT Nov 2016
- Multiple sclerosis helped some by 10,000 IU of vitamin D daily avg. for 3 months – RCT Sept 2016
- Vitamin D has already cleared 100 percent of lesions from over 1,000 MS patients in Brazil
- Dr. Coimbra explains his treatment with high dose vitamin D for multiple sclerosis – Feb 2015
- No multiple sclerosis relapses during pregnancy if 50,000 IU of Vitamin D weekly – RCT April 2015
- 1000 IU per kg Vitamin D for autoimmune diseases – Coimbra Aug 2013
- Optic neuritis progession into Multiple Sclerosis reduced 68 percent by 50,000 IU of vitamin D weekly
- Video by Dr. Coimbra – 95 percent of auto-immune cured with vitamin D in high doses - April 2014
- Autoimmune disorder patients in Brazil helped by vitamin D – video and Facebook – Nov 2012
- Risk of going from pre-MS to MS reduced 68 percent with 7100 IU vitamin D – RCT Dec 2012
- MS helped by average daily 2800 IU vitamin D – RCT Aug 2012
- CureTogether Vitamin D symptoms, treatments, and causes
- Yet again - more than 10000 IU of vitamin D treats MS – July 2011
- Overview MS and vitamin D
10 Most visited pages in Multiple Sclerosis
Background and purpose
Vitamin D status has been associated with inflammatory activity in multiple sclerosis (MS), but it is not known if it is associated with gray matter volume, the loss of which predicts long-term disability in MS. The association of vitamin D levels with brain volume measures and inflammatory activity in patients with clinically isolated syndrome (CIS) was investigated.
Methods
In the phase 2 CIS trial of atorvastatin, 25-hydroxyvitamin D levels were evaluated for their age-adjusted associations with normalized gray matter and brain parenchymal volumes on brain magnetic resonance imaging (MRI). The relationships between 25-hydroxyvitamin D levels and clinical and MRI measures of inflammatory activity were also assessed.
Results
In 65 patients in this substudy, each 25 nmol/l higher 25-hydroxyvitamin D level was associated with 7.8 ml higher gray matter volume (95% confidence interval 1.0, 14.6, P = 0.025). There was a tendency for an inverse association of average 25-hydroxyvitamin D levels and the composite end-point of ≥3 new brain T2 lesions or ≥1 relapse within a year (odds ratio per 25 nmol/l higher 25-hydroxyvitamin D level 0.66, 95% confidence interval 0.41, 1.08, P = 0.096).
Conclusions
Vitamin D status may impact neurodegeneration after CIS, although these results should be replicated in a second study. If confirmed in clinical trials, vitamin D supplementation may reduce long-term disability.